| 7.84 0.03 (0.38%) | 12-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.8 | 1-year : | 10.58 |
| Resists | First : | 8.39 | Second : | 9.06 |
| Pivot price | 7.83  |
|||
| Supports | First : | 7.31 | Second : | 6.08 |
| MAs | MA(5) : | 7.77 |
MA(20) : | 7.96 |
| MA(100) : | 7.66 |
MA(250) : | 6.18 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 57.9 |
D(3) : | 50.2 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 9.52 | Low : | 2.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMNM ] has closed below upper band by 49.3%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.01 - 8.05 | 8.05 - 8.08 |
| Low: | 7.64 - 7.69 | 7.69 - 7.73 |
| Close: | 7.77 - 7.84 | 7.84 - 7.9 |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Thu, 09 Nov 2023
Immunome Reports Third Quarter 2023 Financial Results -November 09, 2023 at 08:14 am EST - Marketscreener.com
Wed, 08 Nov 2023
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors - Marketscreener.com
Fri, 20 Oct 2023
Alloy Properties’ 200,000 SQFT Alloy Innovation Center in Bothell Selected as Immunome’s New Headquarters - The Registry
Wed, 04 Oct 2023
Immunome Insider Bought Shares Worth $999996, According to a Recent SEC Filing - Marketscreener.com
Tue, 03 Oct 2023
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel ... - Marketscreener.com
Sun, 01 Oct 2023
Individual investors who hold 51% of Immunome, Inc. (NASDAQ:IMNM) gained 15%, institutions profited as well - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 31.7 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 428 (K) |
| Shares Short P.Month | 198 (K) |
| EPS | -1.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | -215.5 % |
| Operating Margin | -130 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -150.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -4.36 |
| PEG Ratio | 0 |
| Price to Book value | 15.68 |
| Price to Sales | 32.87 |
| Price to Cash Flow | 104.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|